Medical devices — US PTAB Patent Cases
522 decisions indexed
Page 7 of 18 · 522 total
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Samsung and co‑petitioners have filed an IPR petition against Omni MedSci’s 9,651,533 patent, asserting that the dependent claims are obvious over prior art references Lisogurski, Carlson and Tam. They seek institution of the review and a finding of unpatentability under §103.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Samsung and co‑petitioners have filed an IPR petition seeking to invalidate 18 claims of Omni MedSci’s wearable health‑monitoring patent. They argue the claims are obvious over a combination of prior‑art references and that collateral estoppel bars re‑litigation.
ClearCorrect Operating, LLC et al. v.Align Technology, Inc.
The USPTO denied ClearCorrect's request for Director Review of institution decisions in several IPRs, including the case involving Align Technology's orthodontic aligner patent 11,648,090.
ClearCorrect Operating, LLC et al. v.Align Technology, Inc.
ClearCorrect challenges Align Technology’s dental aligner patent in an IPR, and Align seeks to deny the Patent Owner’s Director Review request. The response argues the new RPI theory and trial‑date evidence are improper, and that the Board’s institution decision was correct.
ClearCorrect Operating, LLC et al. v.Align Technology, Inc.
The PTAB affirmed Align Technology’s patent on a dual‑shell dental sheet composition, finding none of the challenged claims unpatentable after a detailed obviousness analysis involving Hinz, Durasoft data sheets, and Sun.
ClearCorrect Operating, LLC et al. v.Align Technology, Inc.
The PTAB affirmed all claims of Align Technology’s ‘630 patent after finding ClearCorrect’s obviousness arguments unpersuasive. No claim was deemed unpatentable.
ClearCorrect Operating, LLC et al. v.Align Technology, Inc.
The USPTO denied ClearCorrect’s request for Director Review of the institution decisions in five IPRs involving Align Technology’s patents, leaving the institution outcomes intact.
ClearCorrect Operating, LLC et al. v.Align Technology, Inc.
The PTAB affirmed Align Technology’s patent on a multilayer dental sheet composition, finding none of the ClearCorrect‑challenged claims unpatentable.
ClearCorrect Operating, LLC et al. v.Align Technology, Inc.
ClearCorrect has filed an IPR petition seeking to invalidate Align Technology’s 11,154,384 patent covering multilayer dental aligners. The petition argues the claims are obvious over prior‑art references such as Tadros, Kalili, Porter, Wen, and Texin 990R.
ClearCorrect Operating, LLC et al. v.Align Technology, Inc.
ClearCorrect Operating successfully convinced the PTAB to institute review on all claims, arguing that Align Technology's dental aligner patents are obvious under 35 U.S.C. §102 and §103. The Board accepted the petitioner's arguments regarding material substitutions (Tritan for polycarbonate) and combining prior art references into a multilayer device.
ClearCorrect Operating, LLC et al. v.Align Technology, Inc.
The PTAB decided to institute the IPR proceedings against Align Technology's patent (10973613) after Petitioner ClearCorrect demonstrated a reasonable likelihood of prevailing. The Board found that combining prior art references like Tadros, Kalili, and Texin 990R was motivated by POSITA with reasonable expectation of success.
Terumo BCT, Inc. v.Haemonetics Corporation
Terumo BCT argues that the IPR on Haemonetics’ blood‑apheresis patent should remain instituted, emphasizing that the disputed “controller” term is undisputed and that prior‑art devices disclose it.
Terumo BCT, Inc. v.Haemonetics Corporation
Haemonetics Corp. seeks Director review to vacate the institution of an IPR filed by Terumo BCT over its plasma‑apheresis patent. The Owner argues the petitioner’s inconsistent claim‑construction positions and failure to comply with 37 C.F.R. § 42.104(b)(3) warrant denial. The request cites recent Director precedents to support vacatur.
Terumo BCT, Inc. v.Haemonetics Corporation
Terumo BCT has filed an IPR petition challenging all 20 claims of Haemonetics’ plasma‑collection patent, asserting anticipation and obviousness over multiple prior‑art references. The petition outlines five grounds based on Lavender and other patents.
Straumann USA, LLC et al. v.Smart Denture Conversions, LLC.
Straumann USA has filed a post‑grant review petition against Smart Denture Conversions’ U.S. Patent 12,156,781 covering dental implant fasteners. The petition alleges indefiniteness, lack of written description, enablement, and obviousness over several prior‑art references. Straumann seeks institution of the review and cancellation of all 16 claims.
ZEPP HEALTH CORPORATION v.Worcester Polytechnic Institute
Zepp Health and Worcester Polytechnic Institute have entered a settlement that resolves all disputes over U.S. Patent 9,713,428. The parties filed a joint motion to terminate the inter partes review, which is pending before the Board.
Shenzhen Root Technology Co., Ltd. et al. v.Willow Innovations, Inc. et al.
Court decision.
Shenzhen Root Technology Co., Ltd. et al. v.Willow Innovations, Inc. et al.
Shenzhen Root Technology Co., Ltd. successfully petitioned the PTAB to institute an IPR against Willow Blossom Holdco Limited's breast pump patent (11813381). The Board found a reasonable likelihood of unpatentability based on multiple grounds of obviousness under 35 U.S.C. § 103, citing combinations of prior art references like Chang and Fang.
SeaSpine Holdings Corporation et al. v.Jackson, Roger
SeaSpine petitions the PTAB to invalidate a spinal‑implant patent, arguing that its claims are obvious over long‑standing screw‑thread designs disclosed in Kirschman, Higbee, Johnson, Boschert and a 2005 publication.
SeaSpine Holdings Corporation et al. v.Jackson, Roger
The PTAB denied an IPR petition filed by SeaSpine Holdings against Roger P. Jackson because the patent owner had disclaimed all challenged claims of U.S. Patent No. 11,399,873 B2.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s 11,697,012 patent covering hemostasis valves after finding Imperative Care’s petition shows a reasonable likelihood of success on at least one claim.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB has instituted inter partes review on all 15 claims of Inari Medical’s embolism‑treatment patent after finding Imperative Care’s obviousness arguments sufficiently persuasive.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB has instituted an inter partes review of Inari Medical’s ’291 hemostasis valve patent after finding Imperative Care’s petition shows a reasonable likelihood of success. All 16 challenged claims are now under review.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s hemostasis valve patent after finding Imperative Care’s likelihood of success on at least one claim. All nine claims are now under review.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB granted institution of an inter partes review (IPR2025-01562) filed by Imperative Care against Inari Medical’s patent 11,844,921 after finding a reasonable likelihood of unpatentability.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB held that all nine claims of Inari Medical’s hemostasis‑valve patent are unpatentable, finding anticipation by Schaffer and obviousness over combinations with Hartley, Eller and Garrison. The decision hinges on the Board’s construction that the claimed filament must be flexible, which the prior art does not disclose.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB granted Imperative Care’s petition to institute inter partes review of Inari Medical’s hemostasis‑valve patent, finding a reasonable likelihood of unpatentability for claims 1‑9.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB denied Imperative Care's petition to institute an IPR against Inari Medical's embolism‑treatment patent, finding no reasonable likelihood of unpatentability. The petition relied on anticipation and obviousness over Garrison and other references, but lacked sufficient particularity.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB held that Imperative Care proved all nine claims of Inari Medical’s 11,697,011 B2 hemostasis valve patent are unpatentable, finding the term “filament” must be flexible and that the prior art renders the claims obvious.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
Imperative Care has filed an IPR petition challenging Inari Medical’s 11,844,921 hemostasis valve patent, alleging anticipation and obviousness over Schaffer, Hartley, and Eller references.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.